ReviewJournal of drug delivery2018
Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering.
Review in Journal of drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 57 citations in OpenAlex.
- Engineering Inhalable Carboxymethyl Chitosan-Swellable Microgels for Pulmonary Delivery of Charged Hydrophilic Molecules.Gels (Basel, Switzerland) · 2025Article
- Advancing pulmonary therapy: the role of dry powder inhalation technology in lung disease management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Fabrication and evaluation of solidified nanoemulsion designs for systemic delivery of atorvastatin through the lung.Scientific reports · 2025Article
- Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants.Molecular therapy. Methods & clinical development · 2025Article
- Particle surface coating for dry powder inhaler formulations.Expert opinion on drug delivery · 2025Review
- Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery.Advanced healthcare materials · 2022Article
- Proof-of-Concept for Adjusted Surface Energies and Modified Fines as a Novel Concept in Particle Engineering for DPI Formulations.Pharmaceutics · 2022Article
- Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.Current drug metabolism · 2022Article
- Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?Cancers · 2021Review
- Repurposing drug molecules for new pulmonary therapeutic interventions.Drug delivery and translational research · 2021Review
- Moisture-Resistant Co-Spray-Dried Netilmicin with l-Leucine as Dry Powder Inhalation for the Treatment of Respiratory Infections.Pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhalation therapy has strong history of more than 4000 years and it is well recognized around the globe within every culture. In early days, inhalation therapy was designed for treatment of local disorders such as asthma and other pulmonary diseases. Almost all inhalation products composed a simple formulation of a carrier, usually
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.